SavedAdd your journal

Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2021 / Cilt: 12 - Sayı: 3

Fecal S100A12 as a Biomarker in Behcet’s Disease

Cem ŞİMŞEK
Berkan ARMAĞAN
Benazir HYMABACCUS
Alper SARI
Abdulsamet ERDEN
Levent KILIÇ
Ali AKDOĞAN
Pages
616–624
Publication Date
2021-07-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Fecal calprotectin levels were six-fold higher in BD than controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Öz Background: Gastroinestinal involvement in Behcet’s disease impacts morbidity and mortality.
📊
Key Findings & Data:Fecal S100A12 is an established biomarker in gastrointestinal inflammatory diseases and its serum levels are known to increase in Behcet’s Disease.
💡
Conclusion & Impact:Results: Fecal calprotectin levels were six-fold higher in BD than controls (p
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Anahtar Kelimeler Behcet’s disease · gastrointestinal involvement · S100A12

Özet

Öz Background: Gastroinestinal involvement in Behcet’s disease impacts morbidity and mortality. The diagnosis of gastrointestinal disease requires comprehensive evaluation with endoscopic and radiologic examinations which is costly and impractical. A biomarker is essential for non-invasive detection. Fecal S100A12 is an established biomarker in gastrointestinal inflammatory diseases and its serum levels are known to increase in Behcet’s Disease. In this study, we aimed to tests fecal S100A12 levels in Behcet’s patients, its relation with gastrointestinal symptoms to its potential as a biomarker in gastrointestinal involvement. Methods: We prospectively enrolled 48 cases of Behcet’s disease patients fulfilling International Study Group criteria from a university hospital. We excluded patients with other autoimmune conditions, active or recent infection, using NSAIDs and antibiotics. Control group was selected from volunteers who had applied to the rheumatology outpatient clinic. Patients with BD were categorized into 5 groups according to organ involvement. Also we evaluated and recorded disease activity with the BDCAF 2006. Fecal S100A12, fecal calprotectin and acute phase reactants were also collected. Results: Fecal calprotectin levels were six-fold higher in BD than controls (p

🔖

Cite This Article

ŞİMŞEK, C., ARMAĞAN, B., HYMABACCUS, B., SARI, A., ERDEN, A., KILIÇ, L., AKDOĞAN, A. (2021). Fecal S100A12 as a Biomarker in Behcet’s Disease. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 - Sayı: 3, 616–624. https://ajindex.com/articles/216260

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hatemi G, Yazici Y, Yazici H. Behcet's syndrome. Rheum Dis Clin North Am. 2013;39(2):245-61
  2. Sota J, Vitale A, Rigante D, Orlando I, Lucherini OM, Simpatico A, et al. Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behcet's Disease. Isr Med Assoc J. 2018;20(8):517-21
  3. Melikoglu M, Topkarci Z. Is there a relation between clinical disease activity and acute phase response in Behcet's disease? Int J Dermatol. 2014;53(2):250-4
  4. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. Rheumatology (Oxford). 2004;43(1):73-8
  5. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728-33
  6. Hamuryudan V, Fresko I, Direskeneli H, Tenant MJ, Yurdakul S, Akoglu T, et al. Evaluation of the Turkish translation of a disease activity form for Behcet's syndrome. Rheumatology (Oxford). 1999;38(8):734-6
  7. Kopec-Medrek M, Widuchowska M, Kucharz EJ. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54(6):306-9
  8. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56(6):1601-11
  9. Heida A, Van de Vijver E, van Ravenzwaaij D, Van Biervliet S, Hummel TZ, Yuksel Z, et al. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests. Arch Dis Child. 2018;103(6):565-71
  10. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50(3):113-23
  11. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762-71
  12. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation? Amino Acids. 2009;36(3):381-9
  13. Han EC, Cho SB, Ahn KJ, Oh SH, Kim J, Kim DS, et al. Expression of Pro-inflammatory Protein S100A12 (EN-RAGE) in Behcet's Disease and Its Association with Disease Activity: A Pilot Study. Ann Dermatol. 2011;23(3):313-20
  14. Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet's disease: a review. World J Gastroenterol. 2015;21(13):3801-12
  15. Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, et al. Elevated serum levels of calprotectin